Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853058 | 1.00 | ADRB2 (0.48) | ADRB2ADRB1 | |
| SCHEMBL4255093 | 0.93 | ADRB2 (0.51) | ADRB2ADRB1 | |
| SCHEMBL4255091 | 0.93 | ADRB2 (0.51) | ADRB2ADRB1 | |
| SCHEMBL13589426 | 0.92 | ADRB2 (0.53) | ADRB2 | |
| SCHEMBL4256662 | 0.88 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL4012853 | 0.87 | ADRB2 (0.56) | ADRB2 | |
| SCHEMBL4012850 | 0.87 | ADRB2 (0.56) | ADRB2 | |
| SCHEMBL4253746 | 0.87 | ADRB2 (0.52) | ADRB2ADRB1 | |
| SCHEMBL4255206 | 0.87 | ADRB2 (0.51) | ADRB2 | |
| SCHEMBL4261671 | 0.87 | ADRB2 (0.51) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | claimed |
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | ADRB2 901/4885ADRB1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.